Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk and Reward: Pharmacy Compounding of Clinical Materials

This article was originally published in The Gold Sheet

Executive Summary

More and more, drug makers are using pharmacies to compound their clinical materials quicker and cheaper than they themselves could manufacture them – but at what cost? The New England Compounding Center disaster and other incidents over the years make it clear that they must provide careful oversight to ensure quality.


Related Content

Manufacturers, Compounders Clash As FDA Prepares Final Offer On Office Compounding
A Lesson on Outsourcing: The NECC Fungal Meningitis Outbreak
NECC Crisis Festered in Ambiguity That Reigns Over Compounding
What FDA Saw at Compounder Behind Fungal Meningitis Outbreak


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts